Bayer will present the latest data from its oncology portfolio at the annual meeting of the American Society of Clinical Oncology (ASCO), to be held in Chicago, USA, from May 31 to June 4, 2024.

Bayer will present the latest prostate cancer data on darolutamide and radium-223 dichloride, a targeted alpha therapy.

The group will also give a late-breaking summary of BAY 2927088 in patients with HER2-mutant non-small cell lung cancer (NSCLC).

Bayer will also present long-term efficacy and safety data from the VICTORIA study of larotrectinib, including outcomes in patients with tropomyosin kinase (TRK) receptor fusion cancer treated with larotrectinib in clinical trials versus patients treated with TRK-free therapies.

Larotrectinib, under the brand name Vitrakvi®, is approved in over 45 countries, including the U.S. and China, for pediatric and adult patients with neurotrophic TRK-fused solid tumors.

Copyright (c) 2024 All rights reserved.